Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Spyre Therapeutics Inc. Common Stock — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.45 (market cap $111.78B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) is far larger — about 15.2× Spyre Therapeutics Inc. Common Stock's market cap, and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) pays a 1.77% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 3 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ITUB | SYRE | |
|---|---|---|
Market Cap | $111.78B | $7.35B |
Volume | 32,206,998 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $10.16 | $108.92 |
52-Week Low | $6.86 | $22.18 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $1.33T | $6.35B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITUB trades at $9.89, down 1.69% today, following recent profit-taking after reaching 52-week highs. The stock shows bullish technical momentum with strong moving average signals, though RSI indicates overbought conditions. Fundamentally, the bank maintains robust profitability with 27.65% net margin and 21.97% ROE, though recent quarters have seen earnings misses. The company recently received preliminary US bank charter approval, expanding its wealth management services for Latin American clients.
Outlook remains cautiously optimistic with analyst consensus at Buy (46%) and price target of $9.80. Key opportunities include US expansion and strong Brazilian market position, while risks include Brazil's high risk-free rate, competitive pressures, and earnings consistency concerns. The stock trades near fair value with P/E of 11.75 and P/B of 2.5.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)
Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.
Read more on ITUB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
